AdvanCell
AdvanCell develops targeted alpha radiopharmaceuticals for cancer using Lead-212, with integrated isotope supply and manufacturing.
$315MSeries D
Role not disclosedCC
Catalio Capital Management
Activity from announced rounds
Activity in this selectionAustralia · Oct 15, 2026 · Jan 1, 2026
Catalio Capital Management is an investment manager whose official company communications identify BigHat Biosciences and Basecamp Research.
Recorded funding activity
BigHat combines AI and synthetic biology to engineer antibody therapeutics. Basecamp builds biological models from genomic data for therapeutic design, while Enveda discovers biologically active molecules from nature. The financings represent different routes from biological data to experimental medicines.
Sources
- Rounds participated in
- 1
- Confirmed lead rounds
- — 1 roles undisclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $315M 1 disclosed · full round size, not this investor’s share